Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01489566
Recruitment Status : Unknown
Verified December 2011 by Shenzhen Kangzhe Pharmaceutical Co., Ltd..
Recruitment status was:  Enrolling by invitation
First Posted : December 9, 2011
Last Update Posted : December 14, 2011
Fudan University
Medpace, Inc.
Information provided by (Responsible Party):
Shenzhen Kangzhe Pharmaceutical Co., Ltd.

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : March 2013
  Estimated Study Completion Date : August 2013